新闻发布 - Huya Bioscience International

HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries

January 9, 2020/in 2007 /by hwkA5jb3

Meiji Seika Pharma to Commercialize HUYABIO’s Product in Lymphoma

San Diego, CA, USA – January 8, 2020 – HUYA Bioscience International CEO & Executive Chair, Dr. Mireille Gillings announced the appointment of Meiji Seika Pharma (Meiji) as an exclusive distributor for its lymphoma product, HBI-8000, in Japan. Meiji also acquired exclusive rights for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors

June 8, 2018/in 2018 /by hwkA5jb3

San Diego, CA, USA – June 4, 2018 – HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it is at a key stage in the company’s development of HBI-8000, HUYA’s lead novel epigenetic drug with important immunomodulatory properties. HUYA is conducting a Phase 2 trial of HBI-8000 in the US, investigating efficacy and safety in combination with nivolumab for the treatment of solid tumors.

HUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOP

July 10, 2017/in 2017 /by hwkA5jb3

San Diego, CA, USA – July 10, 2017 – HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with Suzhou BioTOP Technical Service Co., Ltd. (referred to as BioTOP). The collaboration will focus on promoting the development of biomedical innovations from companies and research organizations in Suzhou BioBay that help to meet the increasing demand to fill global pharmaceutical pipelines.

HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration

January 25, 2017/in 2017 /by huyausa

San Diego, CA, USA – January 18, 2017 –HUYA Bioscience International (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

HUYA Bioscience International Sponsors 12th Annual Scrip Awards ‘Best New Drug’ Category

December 14, 2016/in 2016 /by hwkA5jb3

San Diego, CA, USA – December 14, 2016 – For the second straight year, HUYA Bioscience International (HUYA) was a proud sponsor of the Best New Drug category at the Annual Scrip Awards.

HUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016

March 29, 2016/in 2016 /by huyausa

Recognized for Visionary Leadership Within Asia’s Pharmaceutical Industry

San Diego, CA, USA – March 24, 2016 –HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9^th BioPharma Asia Convention 2016.

HUYA Bioscience International Celebrates 10 Years in China

March 23, 2016/in 2016 /by huyausa

Biopharma Company with Joint HQ in Shanghai & San Diego Commemorates a Decade of Innovation

Shanghai, China – March 22, 2016 –HUYA Bioscience International (HUYA) celebrated the 10th anniversary of the opening of its first offices in China with a gala dinner at the ‘M on the Bund’ restaurant in Puxi, Shanghai.

HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University

March 18, 2016/in 2016 /by huyausa

Inhibitors of indoleamine 2,3-dioxygenase to be Developed for Oncology Therapy

San Diego, CA, USA – March 15, 2016 –HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.

HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan

December 23, 2015/in 2015 /by huyausa

HBI-8000 granted orphan drug designation for peripheral T-cell lymphoma in Japan

San Diego, CA, USA – December 22, 2015 –HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

HUYA Bioscience International Sponsors ‘Best New Drug’ Category at SCRIP Awards

December 4, 2015/in 2015 /by huyausa

Supports Prestigious Award Recognizing Excellence in Pharmaceutical Development

San Diego, CA, USA – December 3, 2015 –HUYA Bioscience International (HUYA) was a proud sponsor of the ‘Best New Drug’ category at the 11th Annual SCRIP Awards. Dr. Mireille Gillings was a finalist for ‘Executive of the Year’ and HUYA was a finalist for ‘Best Company in an Emerging Market’.